Cargando…
Targeting Innate Receptors with MIS416 Reshapes Th Responses and Suppresses CNS Disease in a Mouse Model of Multiple Sclerosis
Modification of the innate immune cell environment has recently been recognized as a viable treatment strategy for reducing autoimmune disease pathology. MIS416 is a microparticulate immune response modifier that targets myeloid cells, activating cytosolic receptors NOD2 and TLR9, and has completed...
Autores principales: | White, Madeleine, Webster, Gill, O’Sullivan, David, Stone, Sarrabeth, La Flamme, Anne Camille |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909208/ https://www.ncbi.nlm.nih.gov/pubmed/24498172 http://dx.doi.org/10.1371/journal.pone.0087712 |
Ejemplares similares
-
Evaluation of neurological changes in secondary progressive multiple sclerosis patients treated with immune modulator MIS416: results from a feasibility study
por: Webster, Gill A., et al.
Publicado: (2017) -
Safety, tolerability and pharmacodynamics of a novel immunomodulator, MIS416, in patients with chronic progressive multiple sclerosis
por: Luckey, Alison M, et al.
Publicado: (2015) -
Type II Activation of Macrophages and Microglia by Immune Complexes Enhances Th17 Biasing in an IL-6-Independent Manner
por: Stone, Sarrabeth, et al.
Publicado: (2016) -
MIS416 as a siRNA Delivery System with the Ability to Target Antigen-Presenting Cells
por: Mainini, Francesco, et al.
Publicado: (2018) -
Innate IFN-γ ameliorates experimental autoimmune encephalomyelitis and promotes myeloid expansion and PDL-1 expression
por: White, Madeleine P. J., et al.
Publicado: (2018)